Search results for

This month MIP publishes part one of the world's most detailed and authoritative survey of the IP market. Following five months' research, in this issue we list the leading firms in patent prosecution and contentious work in 65 jurisdictions

Crowdsourcing trade marks is becoming more popular and powerful, but care should be taken. Dydra Donath, Laetitia Lagarde, Lisa Pearson, Kate Swaine, Stella Syrianos and Kalina Tchakarova explain

A standoff between the US and Venezuelan governments around currency leaves IP owners in a bind, which lawyers say will be resolved in one of two ways

Fresenius Kabi, Insud Pharma and other generics firms explain how the EU’s SPC manufacturing waiver in its new form will benefit them – but also how its notification clause could make litigation easier for innovator drug firms

CompuMark’s survey of 300 trade mark professionals reveals three-quarters experienced infringement in 2017

Uber, Nestlé and a luggage company speak to Patent Strategy about their due diligence difficulties during mergers and acquisitions and how they avoid the inherent portfolio analysis pitfalls

Vietnam applies the first-to-file principle for trade mark registration and does not require evidence of use or intent to use at the time of filing, or for renewal. For maintaining a registration, though, a trade mark owner or its licensee must use the mark or risk cancellation for non-use. The IP Law stipulates that if a mark has not been used by its owner or a licensee without justifiable reasons for five consecutive years prior to a request for cancellation, except where the use is commenced or resumed at least three months before the request, the registration is vulnerable to cancellation. However, the trade mark owner is not required to submit evidence of use on a regular basis – only when the mark is attacked for non-use.

The judgment will have significant ramifications for brand owners fighting against counterfeits in Singapore

Debiopharm International SA, the appellant, owns a patent for an invention titled "pharmaceutically stable oxaliplatinum preparation". Debiopharm was granted registrations of patent term extension (PTE) for the patent based on approvals provided in the Pharmaceutical Affairs Law for "ELPLAT I.V. Infusion Solution" which is oxaliplatin (equal to oxaliplatinum) preparations. Towa Pharmaceutical Co, Ltd, the appellee, manufactured and sold generic drugs of ELPLAT. Debiopharm sought an injunction on manufacturing, etc of Towa's products alleging that the effect of the extended patent right covers the manufacturing and selling of those products.

The Madrid System could expand beyond 100 member states within the next year if the Organisation Africaine de la Propriété Intellectuelle (OAPI) delivers on its plans to join